Literature DB >> 30220077

The predictive validity of the Strengths and Difficulties Questionnaire for child attention-deficit/hyperactivity disorder.

Kristin Romvig Overgaard1, Kathrine Bang Madsen2, Beate Oerbeck3, Svein Friis3,4, Carsten Obel2.   

Abstract

We need accurate screening measures for attention-deficit/hyperactivity disorder (ADHD) to ensure that children with the disorder are referred for assessment without raising concern for children with normal behaviour. The Strengths and Difficulties Questionnaire (SDQ) provides hyperactivity-inattention (HI), conduct, emotional and peer problem subscales and impact scores that may be used for screening. The aim of the study was to investigate the predictive validity of the Danish version of the parent SDQ HI subscale at the child age of 7 years for subsequent clinically diagnosed ADHD (age 8-15 years). Participants were part of the Danish National Birth Cohort (N = 51,096), and children with ADHD were identified through the Danish National Health registries (n = 943). Receiver operating characteristic analysis showed that the screening accuracy for the HI scores was good (area under the curve = .84). With Cox multivariate regression analysis, we found that SDQ HI subscale scores ≥ 7 with impact gave a nearly 14-fold [hazard ratio (HR) = 13.59] increased risk for ADHD, while conduct and emotional problems indicated low risk (HRs of 1.62 and 1.67, respectively). For the HI subscale to be a sensitive measure for ADHD, a low cutoff (4) was needed, but gave many false screening positives (PPV = .02). Although the diagnostic accuracy of the parent version of the SDQ HI subscale for predicting ADHD was good, our results question the feasibility of screening the general child population for ADHD with only the parent SDQ HI subscale.

Entities:  

Keywords:  ADHD; Cohort study; Patient registries; SDQ

Mesh:

Year:  2018        PMID: 30220077     DOI: 10.1007/s00787-018-1226-9

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  6 in total

1.  Quality of life improvement in children with attention-deficit hyperactivity disorder reduces family's strain: A structural equation model approach.

Authors:  Ilaria Rocco; Maurizio Bonati; Barbara Corso; Nadia Minicuci
Journal:  Child Care Health Dev       Date:  2021-05-08       Impact factor: 2.943

2.  Elevated Gestational IL-13 During Fetal Development Is Associated With Hyperactivity and Inattention in Eight-Year-Old Children.

Authors:  Loreen Thürmann; Gunda Herberth; Ulrike Rolle-Kampczyk; Stefan Röder; Michael Borte; Martin von Bergen; Irina Lehmann; Saskia Trump
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

Review 3.  Early Detection of Behavioral and Emotional Problems in School-Aged Children and Adolescents: The Parent Questionnaires.

Authors:  Carlo Cianchetti
Journal:  Clin Pract Epidemiol Ment Health       Date:  2020-03-18

4.  Clinical characteristics of attention-deficit/hyperactivity disorder in children and adolescents: association with quality of life and behavioral aspects.

Authors:  Marcone de Souza Oliveira; Mayke Felipe Dias Marinho; Stela Maris Aguiar Lemos
Journal:  Rev Paul Pediatr       Date:  2021-10-04

5.  Early Life Exposure to Perfluoroalkyl Substances (PFAS) and ADHD: A Meta-Analysis of Nine European Population-Based Studies.

Authors:  Joan Forns; Marc-Andre Verner; Nina Iszatt; Nikola Nowack; Cathrine Carlsen Bach; Martine Vrijheid; Olga Costa; Ainara Andiarena; Eva Sovcikova; Birgit Bjerre Høyer; Jürgen Wittsiepe; Maria-Jose Lopez-Espinosa; Jesus Ibarluzea; Irva Hertz-Picciotto; Gunnar Toft; Hein Stigum; Mònica Guxens; Zeyan Liew; Merete Eggesbø
Journal:  Environ Health Perspect       Date:  2020-05-06       Impact factor: 9.031

6.  Prenatal maternal infections and children's socioemotional development: findings from the UK Millennium Cohort Study.

Authors:  Hildigunnur Anna Hall; Lydia Gabriela Speyer; Aja Louise Murray; Bonnie Auyeung
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-09-19       Impact factor: 4.785

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.